|
Wednesday, 10 March 2010 10:01 |
|
The National Human Genome Research Institute would receive $534 million under the White House's proposed $32.2 billion budget for the National Institutes of Health, should the 2011 Department of Health and Human Services appropriation pass as it is. That amount would represent an increase of $18 million, or around 3.4 percent, for NHGRI over the 2010 appropriation — meaning that the institute was exempted from the Obama Administration's plan to put a freeze on much of discretionary funding for domestic expenses in 2011. |
|
Read more...
|
|
Wednesday, 10 March 2010 09:55 |
|
Stem cell products developer Stemgent said today that it has started a new business in Scotland that will develop reagents and kits and offer services for use in studying the ubiquitin proteasome pathway (UPP) for drug research. Stemgent, which has operations in Boston and San Diego, will invest roughly $4.5 million over three years in the new venture, which is based in Dundee. |
|
Read more...
|
|
Tuesday, 09 March 2010 09:00 |
|
In connection with the previously announced closing of Spectral Diagnostic Inc.'s ("Spectral") private placement of 48,750,000 units, BioMS Medical Corp., GrowthWorks Canadian Fund Ltd., GrowthWorks Atlantic Venture Fund Ltd., Mavrix Fund Management Inc., Spectral and others entered into an amended and restated voting agreement (the "Voting Agreement"). |
|
Read more...
|
|
Thursday, 04 March 2010 03:32 |
|
Bristol-Myers Squibb’s (BMS) is paying Allergan $40 million up front for AGN-209323, a Phase II-ready product for neuropathic pain, and backup compounds. The deal has a total value of $413 million and includes all potential indications except ophthalmology indications where products are formulated for local delivery to the eye. |
|
Read more...
|
|
Thursday, 04 March 2010 03:28 |
|
The National Heart, Lung, and Blood Institute expects to provide up to $30 million to support a number of centers that will develop diagnostics or treatments for lung diseases and for sleep-disordered breathing. The Centers for Advanced Diagnostics and Experimental Therapeutics in Lung Diseases Stage I (CADET 1) program is aimed at accelerating development of in vitro diagnostic technologies and validation of preclinical markers, as well as discovery of potential therapeutics. |
|
Read more...
|
|
Sunday, 28 February 2010 09:53 |
|
A new grant program from the National Institutes of Health will provide up to $25 million to fund up to eight research centers to study traits or mechanisms across organ systems and diseases and use genetic and cellular research approaches to lung, heart, blood, and sleep disorders. |
|
Read more...
|
|
Sunday, 28 February 2010 09:50 |
|
The National Institutes of Health and the US Food and Drug Administration today unveiled a new joint effort aimed at developing ways to translate new biomedical discoveries through regulation and into pharmacies and hospitals. Focused on advancing and intertwining translational and regulatory science, the initiative will include the formation of a joint NIH-FDA Leadership Council to explore ways to move scientific breakthroughs "from the microscope to the marketplace," Health and Human Services Secretary Kathleen Sebelius said at a press conference at NIH today. |
|
Read more...
|
|
Friday, 26 February 2010 22:25 |
|
A four-institution study intended to improve understanding of the evolution, developmental biology, and physiology of insects is among 10 multidisciplinary, multiple-location research programs or "units" that have been awarded a combined €22.2 million over three years by the Senate of Germany's Deutsche Forschungsgemeinschaft, also known as DFG or the German Research Foundation. |
|
Read more...
|
|
Friday, 26 February 2010 22:00 |
|
The National Institute of Allergy and Infectious Diseases plans to provide $20 million in fiscal 2011 to fund its Partnerships for Biodefense program, which supports development of candidate diagnostics, therapeutics, vaccines, and adjuvants for pathogens and toxins that NIAID has labeled as Category A, B, or C priorities. |
|
Read more...
|
|
Saturday, 20 February 2010 08:45 |
|
 PolyTherics completed a £3 million (roughly $4.71 million) investment round led by Imperial Innovations Group. The funds will be used to further develop and commercialize its latest PEGylation platforms, HiPEG™ and CyPEG, for the development of what the firm terms “biobetter” protein and peptide products.
|
|
Read more...
|
|
|
Wednesday, 10 March 2010 09:59 |
|
Genome Canada has been tabbed to receive C$75 million ($73 million) under the national 2010 budget proposal from Canadian Prime Minister Stephen Harper's administration. This year's budget proposal, which was announced last week by Minister of Finance James Flaherty, is aimed at shifting Canada from a stimulus-oriented approach focused on fending off recession toward a new effort to begin to reduce its deficit. |
|
Read more...
|
|
Wednesday, 10 March 2010 09:32 |
|
Two institutes of the National Institutes of Health will give $24 million over four years to fund research into genotypic and phenotypic connections between lung cancer and chronic obstructive pulmonary disease (COPD), including studies seeking biomarkers and exploring interactions between genetic and environmental factors. |
|
Read more...
|
|
Monday, 08 March 2010 09:19 |
|
Health Affairs this month is devoted to the topic of childhood obesity, with the first study of the group - National, State, And Local Disparities In Childhood Obesity - pointing out that "new data from the 2007 National Survey of Children's Health show that the percentage of children ages 10-17 who are overweight ... remained stable, while the national prevalence of obesity (BMI in the ninety-fifth percentile and higher) grew significantly, from 14.8 percent in 2003 to 16.4 percent in 2007. |
|
Read more...
|
|
Thursday, 04 March 2010 03:29 |
|
The director of the University of Arizona's newly-formed Clinical and Translational Science Institute hopes the research hub, along with other recently-completed and planned facility projects, will succeed where two past attempts failed in winning for the university a long-sought membership in the National Institutes of Health's Clinical and Translational Science Awards consortium. |
|
Read more...
|
|
Thursday, 04 March 2010 03:15 |
|
The Oregon State legislature has approved a bill giving $9 million to fund construction of an Oregon State University institute that would study marine genomics and marine mammals. The Marine Mammal Institute and Marine Genomics Program will be housed in a new 42,000-square-foot facility at the Hatfield Marine Science Center in Newport. |
|
Read more...
|
|
Sunday, 28 February 2010 09:53 |
|
Two scientists at Melbourne, Australia's Walter and Eliza Hall Institute have won A$1.8 million (US$1.5 million) in five-year grant fellowships to support cancer genetics and epigenetics research. Marnie Blewitt, a researcher and lab head at the Institute, won the inaugural Dyson Fellowship to fund her studies of cancer epigenetics. |
|
Read more...
|
|
Friday, 26 February 2010 22:27 |
|
Seattle's Sage Bionetworks, a non-profit medical research organization, will use a grant of $6.7 million from the National Cancer Institute to establish a new interdisciplinary research and training center, Sage said today. Funded under the NCI's Integrative Cancer Biology Program (ICBP) the center will conduct genomics and other biomedical research, and will support training of four postdoctoral researchers each year. |
|
Read more...
|
|
Friday, 26 February 2010 22:21 |
|
Two institutes of the National Institutes of Health intend to fund a proteomics data resource to house protein sequence information that researchers can search and use to support their biomedical research. |
|
Read more...
|
|
Saturday, 20 February 2010 08:47 |
|
 Immune Targeting Systems (ITS) secured a £8.65 million (about $13.57 million) extension to its Series A round of equity financing, taking the total raised to £13.5 million (approximately $21.18 million). All the company’s key investors participated, and ITS says that it will keep the round open to new investors until mid-2010.
|
|
Read more...
|
|
Saturday, 20 February 2010 08:44 |
|
Genentech and Biogen Idec reported receiving an FDA go-ahead for Rituxan® in combination with fludarabine and cyclophosphamide (FC) as a treatment for CD20-positive chronic lymphocytic leukemia. Approval covers the combination therapy in people with either previously treated or untreated disease. |
|
Read more...
|
|
